pf-05236812
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01193608)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinImmunity, passive
APP immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-05236812
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01369225 | Phase 1 | Jul 1, 2011 | Johnson and Johnson, Pfizer |
| NCT01193608 | Phase 1 | Sep 1, 2010 | Johnson and Johnson, Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 0 | 1 | 2010 |
| Pfizer | For profit | 2 | 2 | 1 | 2010 |
2 organizations
Page 1 / 1